# HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct07232875/  
OnCo record `nct07232875` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of HRS-4642 + AG in pancreatic ductal adenocarcinoma, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT07232875 by Jiangsu HengRui Medicine Co., Ltd., with 588 participants planned, started 2025-11-21 and due to reach its primary completion in 2029-04. Interventions recorded: HRS-4642 + AG and HRS-4642 placebo + AG.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07232875
- Phase: 3
- Setting: a Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial of HRS-4642 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as First-Line Therapy in Patients With Advanced or Metastatic Pancreatic Carcinoma Harboring KRAS G12D Gene Mutation
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 588

## Sources

- ClinicalTrials.gov NCT07232875: https://clinicaltrials.gov/study/NCT07232875

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07232875.json